Synthesis, Characterization, and Preliminary Evaluation of Ferulic Acid Derivatives Containing Heterocyclic Moiety

This study aimed to synthesize new ferulic acid derivatives through preparing new compounds containing a heterocyclic group that are expected to be biologically effective for diagnosis and studying pharmacological efficacy through these groups. These new compounds are primarily screened (in vitro) for their cytotoxic activity against human lung (A549) and breast (MCF-7) cancer cell line, 1H-NMR, 13C-NMR spectroscopy, and FT-IR spectra. Pharm kinetic study by Swiss ADME suite was examined, utilizing molecular docking software (GOLD suite v. 5.7.1), the selectivity for EGFR and ER-receptors, cytotoxicity evaluation tested compounds in vitro IC50 showed compounds (4a and 4b) are more active anticancer (478.32 and 561.12 µg/mL), respectively than reference erlotinib (582.73), while the compounds 4a, 4b, and 4c, respectively is the more active anticancer than standard tamoxifen (392.3 µg/mL).